{"id":"W4410384052","doi":"10.1016/j.jhep.2025.05.003","title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","year":2025,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Durvalumab; Biliary tract cancer; Medicine; Topaz; Biliary tract; Chemotherapy; Cancer; Oncology; Internal medicine; Gemcitabine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003972869,0.0001861685,0.0008982645,0.0001498238,0.00007262577,0.00001317676,0.0002257294,0.00007986945,0.0001670926],"category_scores_gemma":[0.00008827003,0.0001209913,0.0001839003,0.0002285875,0.00008236893,0.00009188789,0.00005274511,0.0005139688,0.000002796767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002801887,"about_ca_system_score_gemma":0.0005425445,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001354501,"about_ca_topic_score_gemma":0.001889858,"domain_scores_codex":[0.9984253,0.0001859812,0.0006553652,0.0002238421,0.0002494323,0.000260047],"domain_scores_gemma":[0.9989523,0.0002854335,0.0002670886,0.0002829134,0.0001494452,0.00006285779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006804178,0.0009968157,0.9699854,0.00001471522,0.0006008958,0.0005207722,0.002251665,0.00001312493,0.0005696491,0.00002891897,0.005573903,0.01263999],"study_design_scores_gemma":[0.06065262,0.001169025,0.9210705,0.0001551625,0.0003891105,0.00009820268,0.003336643,0.00009709049,0.0004804385,0.0003193532,0.01207273,0.0001591999],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9724988,0.009169182,0.00002880235,0.01612548,0.001319978,0.0004010311,0.00001438138,0.00001127462,0.0004310253],"genre_scores_gemma":[0.994314,0.002380435,0.00009859566,0.002754834,0.0002863654,0.00001790576,0.000003791218,0.00001481912,0.0001292935],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05384844,"threshold_uncertainty_score":0.4933884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01994324393049175,"score_gpt":0.341977400279399,"score_spread":0.3220341563489073,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}